# Teva Pharmaceutical Industries

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/teva-pharmaceutical-industries
Canonical HTML page: https://getyourbrief.com/entity/teva-pharmaceutical-industries

## Timeline

- **2026-02-23**: Lawsuit Announced — Rosen Law Firm announces the filing of the class action lawsuit and lead plaintiff opportunity.
- **2026-02-20**: Teva Legal Victory — Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
- **2025-12-30**: Class Period Ends — The cutoff date for the class action, often coinciding with a corrective disclosure.
- **2024-10-31**: Class Period Begins — The start date for the alleged period of securities fraud and misleading statements.

## Recent coverage (4 stories, network-wide)

### CBRE Ups FY2026 EPS View to $7.80-$7.90 as Real Estate Tech Demand Booms
2026-08-05 14:17:03 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CBRE Group's above-consensus EPS guidance underscores the commercial real estate sector's momentum, driven by technology-driven services. For PropTech startups and investors, it signals growing client spending on smart buildings, data analytics, and digital brokerage platforms.
Full story: https://getproptechbrief.com/story/cbre-fy2026-guidance-proptech

### Teva's $1.91-$2.11 EPS Guidance Misses Consensus, Testing Pharma Resilience
2026-08-05 14:16:51 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Full story: https://gethealthbrief.com/story/teva-fy2026-guidance-health

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### Corcept Therapeutics Faces Securities Fraud Suit Following Class Period Volatility
2026-02-24 12:34:03 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 10

Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
Full story: https://getfinancebrief.com/story/corcept-therapeutics-securities-fraud-lawsuit-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.